share_log

JP Morgan Maintains Neutral on Alnylam Pharmaceuticals, Raises Price Target to $170

Benzinga ·  Feb 1 09:16

JP Morgan analyst Jessica Fung maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Neutral and raises the price target from $150 to $170.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment